Skip to main
LH
LH logo

LH Stock Forecast & Price Target

LH Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 42%
Buy 35%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

Laboratory Corp. of America (Labcorp Holdings) is positioned for a strong growth trajectory, with the Diagnostics segment reporting a robust year-over-year revenue growth of 7.9%, culminating in $2.52 billion for the quarter. Additionally, the company has projected revenue growth for 2024 between $12.9 billion to $13.1 billion, representing an increase of 6.4% to 7.5%, which reflects a significant uptick from historical averages. The improved adjusted operating margin of 15.2%, supported by organic growth and efficiencies from LaunchPad, further reinforces the company's operational strength and financial stability.

Bears say

Labcorp Holdings has lowered its revenue guidance for the upcoming fiscal year, projecting a modest growth of only 3.7% to 5.0%, which reflects a concerning trend in the company’s financial health. The impact of pricing cuts under the PAMA regulations and significant challenges in capturing synergies from acquisitions are expected to contribute to downward pressure on profit margins, further complicating the company's growth outlook. Additionally, the company's biopharma revenue growth of 1.1% year-over-year fell short of expectations, highlighting underlying operational difficulties and intensified competition within the market.

LH has been analyzed by 31 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 35% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Labcorp Holdings Inc (LH) Forecast

Analysts have given LH a Buy based on their latest research and market trends.

According to 31 analysts, LH has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $222.98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $222.98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Labcorp Holdings Inc (LH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.